An overview of depot buprenorphine
This webinar will cover the following learning objectives:
- Outline the role of buprenorphine depots in the treatment of opioid dependence
- Compare the pharmacokinetic profiles, evidence for use, adverse effects, and patient experiences of buprenorphine depot formulations
- Identify key considerations for buprenorphine depot use and management in a hospital setting and special patient populations
- Describe the process and dosing considerations of transferring a patient from sublingual to depot buprenorphine
- Overview studies examining buprenorphine depots, including the DEBUT and UNLOC-T studies
- Review case examples of buprenorphine depot use in practice
This webinar will commence at 2:00pm AEDT
- Register in the purple box below, then click on 'cart' at the top of the page (or under your menu options) and continue through checkout.
- Still having trouble registering? Follow our handy ‘how to’ guide
- Click here to view our Terms and Conditions
* You will receive a confirmation email upon completion of your registration. If you do not receive this within 4 hours, you have not completed your registration and your space is not guaranteed. Please contact the secretariat by emailing email@example.com.
- Dr Adrian Dunlop, Director & Senior Staff Specialist, Drug & Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, NSW; Conjoint Professor, School of Medicine and Public Health, Faculty of Health, University of Newcastle, Newcastle, NSW; President-Elect, Chapter of Addiction Medicine, Royal Australian College of Physicians, Melbourne, Vic
- Standard 3.1.2 Assess medication management practices and needs
- Standard 3.2.3 Dispense medicines (including compounded medicines) in consultation with the patient and/or prescriber
- Standard 3.3.1 Undertake a clinical review
*National competency standards framework for pharmacists in Australia, 2016
This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credit), suitable for inclusion in an individual pharmacist's CPD plan. The accreditation number is S2020/57.